Omeros (OMER) Upgraded to “Hold” by ValuEngine

Omeros (NASDAQ:OMER) was upgraded by ValuEngine from a “sell” rating to a “hold” rating in a research report issued on Friday.

Several other research firms also recently commented on OMER. Zacks Investment Research raised Omeros from a “sell” rating to a “hold” rating in a report on Wednesday, November 15th. Wedbush reissued an “outperform” rating and issued a $47.00 price objective on shares of Omeros in a report on Tuesday, November 28th. Maxim Group reissued a “buy” rating and issued a $24.00 price objective on shares of Omeros in a report on Monday, November 6th. Finally, HC Wainwright set a $30.00 price objective on Omeros and gave the company a “buy” rating in a report on Tuesday, January 23rd. Five research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $34.14.

Omeros (NASDAQ OMER) traded down $0.98 during midday trading on Friday, hitting $15.19. The stock had a trading volume of 537,873 shares, compared to its average volume of 615,235. The firm has a market cap of $729.18, a P/E ratio of -11.78 and a beta of 3.30. The company has a current ratio of 4.77, a quick ratio of 4.74 and a debt-to-equity ratio of 8.99. Omeros has a 12 month low of $9.57 and a 12 month high of $27.09.

Omeros (NASDAQ:OMER) last released its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.18. The company had revenue of $21.66 million during the quarter, compared to analyst estimates of $17.82 million. The company’s quarterly revenue was up 91.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.34) EPS. equities analysts predict that Omeros will post -0.98 EPS for the current fiscal year.

A number of institutional investors have recently made changes to their positions in the business. Ingalls & Snyder LLC lifted its holdings in Omeros by 3.4% during the 4th quarter. Ingalls & Snyder LLC now owns 5,335,239 shares of the biopharmaceutical company’s stock valued at $103,664,000 after purchasing an additional 174,204 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Omeros by 5.4% during the 2nd quarter. Vanguard Group Inc. now owns 1,825,671 shares of the biopharmaceutical company’s stock valued at $36,341,000 after purchasing an additional 94,280 shares during the last quarter. State Street Corp lifted its holdings in Omeros by 7.3% during the 2nd quarter. State Street Corp now owns 987,057 shares of the biopharmaceutical company’s stock valued at $19,652,000 after purchasing an additional 66,827 shares during the last quarter. Northern Trust Corp lifted its holdings in Omeros by 6.4% during the 2nd quarter. Northern Trust Corp now owns 572,576 shares of the biopharmaceutical company’s stock valued at $11,397,000 after purchasing an additional 34,328 shares during the last quarter. Finally, Tocqueville Asset Management L.P. lifted its holdings in Omeros by 0.7% during the 3rd quarter. Tocqueville Asset Management L.P. now owns 480,896 shares of the biopharmaceutical company’s stock valued at $10,397,000 after purchasing an additional 3,430 shares during the last quarter. 50.26% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Omeros (OMER) Upgraded to “Hold” by ValuEngine” was reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/02/04/omeros-omer-upgraded-to-hold-by-valuengine.html.

About Omeros

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply